Tiziana Life Sciences Files 20-F/A Amendment

Ticker: TLSA · Form: 20-F/A · Filed: May 8, 2025 · CIK: 1723069

Sentiment: neutral

Topics: amendment, annual-report, sec-filing

TL;DR

Tiziana Life Sciences amended its 2024 annual report, check for updates.

AI Summary

Tiziana Life Sciences Ltd filed an amendment (20-F/A) to its annual report for the fiscal year ended December 31, 2024. The filing, submitted on May 8, 2025, is an amendment to a previous filing and pertains to the company's ongoing reporting obligations under the Securities Exchange Act of 1934.

Why It Matters

This filing provides updated information for the fiscal year 2024, which is crucial for investors to assess the company's financial health and strategic direction.

Risk Assessment

Risk Level: medium — As a 20-F/A filing, it's an amendment to an annual report, indicating potential updates or corrections to previously disclosed information, which warrants careful review.

Key Players & Entities

FAQ

What specific information is being amended in this 20-F/A filing?

The filing is an amendment to the Form 20-F for the fiscal year ended December 31, 2024, but the specific details of the amendments are not provided in the header information.

When was the original 20-F filing for the fiscal year 2024 submitted?

The filing header does not specify the date of the original 20-F filing, only that this is Amendment No. 1.

What is Tiziana Life Sciences Ltd's primary business sector?

Tiziana Life Sciences Ltd is classified under Pharmaceutical Preparations (SIC code 2834).

Where is Tiziana Life Sciences Ltd headquartered?

The company's business and mailing address is 3rd Floor, 11-12 St. James's Square, London, England, SW1Y 4LB.

What is the SEC file number for Tiziana Life Sciences Ltd?

The SEC file number for Tiziana Life Sciences Ltd is 001-38723.

Filing Details

This Form 20-F/A (Form 20-F/A) was filed with the SEC on May 8, 2025 regarding Tiziana Life Sciences Ltd (TLSA).

View full filing on EDGAR

View Full Filing

View this 20-F/A filing on SEC EDGAR

View on Read The Filing